^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Excerpt:
...- Patients are eligible regardless of their FLT3 mutation status....
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY

Published date:
05/12/2022
Excerpt:
Treatment with Gilteritinib and Quizartinib as monotherapy is an effective and tolerable option for patients with R/R FLT3-mutated AML in real-life, with similar response rates…
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia

Published date:
08/03/2020
Excerpt:
Overall survival was predicted to be significantly better with quizartinib 200 mg administered every 48 h vs every 24 h in patients with FLT3 aberrations.
DOI:
10.1007/s00280-020-04114-z
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

Published date:
11/04/2020
Excerpt:
In the FLT3 positive AML cohort, six patients were registered and one achieved remission by quizartinib after progression on gilteritinib.
DOI:
https://doi.org/10.1182/blood-2020-139147